KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Non Operating Income (2016 - 2025)

TherapeuticsMD's Non Operating Income history spans 16 years, with the latest figure at $972000.0 for Q4 2025.

  • For Q4 2025, Non Operating Income rose 32.24% year-over-year to $972000.0; the TTM value through Dec 2025 reached $3.3 million, down 1.39%, while the annual FY2025 figure was $3.7 million, 0.85% down from the prior year.
  • Non Operating Income reached $972000.0 in Q4 2025 per TXMD's latest filing, up from $912000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $25.3 million in Q4 2021 to a low of -$22.8 million in Q1 2022.
  • Average Non Operating Income over 5 years is -$2050.0, with a median of $268000.0 recorded in 2024.
  • Peak YoY movement for Non Operating Income: tumbled 689.47% in 2022, then skyrocketed 2898.28% in 2024.
  • A 5-year view of Non Operating Income shows it stood at $25.3 million in 2021, then crashed by 99.96% to $11000.0 in 2022, then surged by 145.45% to $27000.0 in 2023, then surged by 2622.22% to $735000.0 in 2024, then skyrocketed by 32.24% to $972000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Non Operating Income are $972000.0 (Q4 2025), $912000.0 (Q3 2025), and $1.2 million (Q2 2025).